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Reply to the Editor:
My colleagues and I thank Lange and
colleagues for pointing out that we omit-
ted mentioning the importance of volatile
anesthetics and ischemic preconditioning
(IPC) in a number of animal models and
possibly human beings. For example,
Kersten and coworkers1 showed that
halothane preconditioning in barbiturate-
anesthetized dogs led to a profound in-
farct size reduction (25.3%  2.9% to
11.8%  2.7%) and that this reduction
was as effective as IPC (9.6%  2.0%).
We were remiss in not discussing these
results and their importance to IPC.
Lange and colleagues also stated, “Anes-
thetic preconditioning significantly re-
duces arrhythmias after ischemic peri-
ods.” The antiarrhythmic effect of
volatile anesthetics is more problematic.
Recently Owczuk and associates2 dis-
cussed how desflurane can prolong the
QTc interval and may result in lethal
cardiac arrhythmias. Huneke and co-
workers3 also reported that halothane,
and to a lesser extent isoflurane and
sevoflurane, may lead to ventricular ar-
rhythmias by shortening the refractory
period. In addition, volatile anesthetics
are known to inhibit a number of voltage-
gated potassium ion channels, which
could further increase the risk of ventric-
ular tachycardia in predisposed patients.3
It is unfortunate that most animal studies
investigating volatile anesthetics and IPC
rarely report the incidence and duration
of arrhythmias during ischemia-reperfu-
sion. On the other hand, we reported that
pretreating the heart with an intravenous
solution of the adenosine A1 receptor
agonist 2-chloro-N6-cyclopentyladenosine and
sodium ion fast-channel modulator lidocaine
(A1L) administered 5 minutes before and
during 30 minutes of acute regional ischemia
in the rat in vivo resulted in no deaths, virtu-
ally no severe ventricular arrhythmias and an
infarct size equivalent to that seen with IPC.4
Finally, Lange and colleagues believe it is
unlikely that the administration of a selective
A1 agonist plus a volatile anesthetic could
further enhance cardioprotection. However,
we believe the combination may reduce the
amount of each agent needed to exert cardio-
protection; that is, the A1 receptor agonist
may reduce the effective therapeutic thresh-
old of the volatile anesthetic agent. This con-
cept was recently reported by Chiari and col-
leagues,5 in whose study postconditioning
during early reperfusion reduced the concen-
tration of isoflurane necessary to exert car-
dioprotection. Because the underlying mech-
anisms of volatile anesthetics and the A1L
combination are not fully understood, the
synergistic effects of volatile anesthetics and
A1 analogs (or A1L) remain to be deter-
mined. Moreover, modulating cardiac volt-
age-gated sodium ion fast channels with local
anesthetics has received surprisingly little at-
tention in IPC strategies, despite the resetting
of the resting membrane potential toward a
more depolarized state during ischemic inju-
ry.3 To quote nineteenth century essayist and
politician Benjamin Disraeli, “What we an-
ticipate seldom occurs; what we least ex-
pected generally happens.”5 Importantly, our
work has shown that it is the combination of
A1 agonist (or adenosine) and lidocaine ad-
ministration that confers functional, electri-
cal, and metabolic protection during myocar-
dial ischemia-reperfusion.3 It would be of
interest to study the effects of volatile anes-
thetics in the presence of the combination of
A1 agonist (or adenosine) and lidocaine dur-
ing and after acute myocardial ischemia in
clinically relevant experimental models.6
Geoffrey P. Dobson, MSc, PhD
Department of Physiology and Pharmacology
James Cook University, Townsville,
Queensland, Australia
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Management of pediatric airway
obstruction
To the Editor:
We read with interest Vinograd and col-
leagues’ article1 on the management of
airway obstruction in children by using self-
expandable metal stents (SEMS). We com-
mend the authors on a thorough and detailed
description of the difficulties encountered in
treating children with this complex problem.
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